Share
Print
Innovation platforms for advanced therapies of the future
Details
Location:EU 27, Switzerland
Funding agency:
Grantmaking entity type:Development Institution
Description
Call updates:
05 October 2018 11:58
A result overview of the evaluation that closed on 18 April 2018 is now available under the "Topic conditions and documents" section.
27 April 2018 09:57
The submission of proposals to the 21 topics of H2020-SC1-2018-Single-Stage-RTD closed on 18 April 2018. A total of 324 proposals were submitted. The number of proposals per topic is as follows:
- SC1-BHC-09-2018 (RIA): 63
01 March 2018 11:36
Notice regarding page limits applicable to proposals: applicants are allowed to remove the page break in the cover page of the template for the technical annex, i.e. the proposal text can start on the cover page.
07 November 2017 00:30
The submission session is now available for: SC1-BHC-09-2018(RIA)
TOPIC : Innovation platforms for advanced therapies of the future
| Topic identifier: | SC1-BHC-09-2018 | ||
| Publication date: | 27 October 2017 | ||
| Types of action: | RIA Research and Innovation action | ||
| DeadlineModel: Planned opening date: |
single-stage 07 November 2017 |
Deadline: | 18 April 2018 17:00:00 |
| Time Zone : (Brussels time) | |||
Pillar: Societal Challenges
Work Programme Year: H2020-2018-2020
Work Programme Part: Health, demographic change and wellbeing
Call : H2020-SC1-BHC-2018-2020
Topic Description
Specific Challenge:Advanced therapies are based on gene, cell or tissue-engineered products which are defined according to the terms of Regulation 1394/2007. So far, only a small number of these products have been placed on the market, and of these, most are for rare diseases. However, in recent years, important discoveries and developments, some unprecedented, have been made in molecular and cell biology and in cell technology, which offer improved opportunities for advanced therapies development. The challenge is to use the new knowledge and new technologies to introduce greater innovation into the advanced therapy development chain as a basis for tackling diseases and conditions affecting large patient groups.
Scope:Building on European strengths and using the definition set out in Regulation (EC) 1394/2007[1], projects should create knowledge, testing and exploitation platforms around innovative concepts for advanced therapy development. Platforms should comprise the components and expertise necessary to create a solid foundation on which to build possible new therapeutic approaches and/or aim to overcome particular development bottlenecks. Possible components could include studying the basic biology of the potential therapy and investigating its mode of action, proof of concept (in vitro, in animal models – where necessary - or first-in–man studies); safety, efficacy, characterisation, refinement and manufacturing of the product could be considered. Projects should also propose a business model for exploiting results and carry out appropriate outreach and public information activities. Examples of issues that have been identified as holding back the field include gene delivery to cells, reducing off-target effects in gene therapy, immunogenicity of potential new therapies, cell homing and tracking, lack of adequate pre-clinical models, or responding to regulatory concerns, such as potency assays, product characterization, or bank-to-bank variability (non-exhaustive list for illustrative purposes only). Sex and gender differences should be investigated, where relevant. Potential ethical issues should be addressed.
The Commission considers that proposals requesting a contribution from the EU of between EUR 12 and 15 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected Impact:- Strengthened competitive position of European advanced therapy research and development.
- Improved perspectives for treating diseases and conditions in large patient groups with advanced therapies.
- Technological progress in the advanced therapy field.
[1]OJ L 324, 10.12.2007, p. 121.
Similar grants
By Locations
Funding agency:
Horizon 2020
Status:
awarded
Location:
EU 27, Switzerland
Funding agency:
Horizon 2020
Status:
awarded
Location:
EU 27, Switzerland
By Sectors
Funding agency:
Gates Foundation
Status:
awarded
Location:
Afghanistan, Albania, Algeria, American Samoa, Angola, Argentina, Armenia, Azerbaijan, Bangladesh, Belarus, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, China, Colombia, Comoros, Congo, Costa Rica, Cote d'Ivoire, Cuba, Dem. Rep. Congo, Djibouti, Dominica, Commonwealth of, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Eswatini (Swaziland), Ethiopia, Fiji, Gabon, Gambia, Georgia, Ghana, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, India, Indonesia, Iran, Iraq, Jamaica, Jordan, Kazakhstan, Kenya, Kiribati, Kosovo, Kyrgyzstan, Laos, Lebanon, Lesotho, Liberia, Libya, Madagascar, Malawi, Malaysia, Maldives, Mali, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Moldova, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Nicaragua, Niger, Nigeria, North Korea, North Macedonia, Pakistan, Palestine / West Bank & Gaza, Papua New Guinea, Paraguay, Peru, Philippines, Romania, Russia, Rwanda, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Sao Tome and Principe, Senegal, Serbia, Sierra Leone, Solomon Islands, Somalia, South Africa, South Sudan, Sri Lanka, Sudan, Suriname, Syria, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Tunisia, Turkey, Turkmenistan, Tuvalu, Uganda, Ukraine, Uzbekistan, Vanuatu, Venezuela, Vietnam, Yemen, Zambia, Zimbabwe
Funding agency:
Horizon Europe
Status:
awarded
Location:
EU 27
grant Background
About the Funding Agency
Horizon 2020 - is a Framework Programme for Research and Technological Development, and is created by the European Union in order to support and encourage research in the European Research Area (ERA). This is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation. The Horizon 2020 programme running from 2014 to 2020 has a €79 billion budget (a 46% increase over FP7).
It is structured around three core pillars:
- Excellent Science (~€24.4bn)
- Industrial Leadership (~€17bn)
- Societal Challenges (~€29.7bn)
Type of projects: mostly grants, no supplies, no works.
In order to see Horizon 2020 opportunities on DevelopmentAid, please click here.
About the Sectors
Health
Covers healthcare services, public health systems, and activities aimed at promoting physical and mental well-being.
Key areas:
- Healthcare services and facilities
- Public health and disease prevention
- Medical equipment, supplies, and services
Research & Innovation
Focuses on collecting data, generating new knowledge, and applying it to develop improved methods, technologies, products, and solutions across sectors.
Key areas:
- Scientific research, studies, and investigations
- Innovation programs and applied R&D initiatives
- Technology development
- Space-related research and exploration themes